Technology | Point of Care Testing | November 10, 2016

Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer

Handheld portable PT/INR analyzer designed for any professional point-of-care setting

Siemens, FDA clearance, Xprecia Stride Coagulation Analyzer, point-of-care testing

November 10, 2016 — Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand-held portable coagulation analyzer. The Xprecia Stride Coagulation Analyzer delivers fast, reliable Prothrombin Time/International Normalized Ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist.

Millions of PT/INR tests are administered worldwide each year as part of therapy monitoring for patients with a host of conditions, including atrial fibrillation, heart valve replacement surgery, deep vein thrombosis and congenital heart defects, among others. The Xprecia Stride Coagulation Analyzer was specifically designed to meet the growing demand for fast and reliable PT/INR results in physician offices and walk-in clinics to help healthcare professionals make informed decisions about patient care.

No bigger than a smartphone and weighing just 10.5 oz, the Xprecia Stride Coagulation Analyzer can be held at virtually any angle and brought directly to the patient’s finger for efficient and comfortable blood sample application.

The device sports an intuitive user interface and features such as an integrated barcode scanner to simplify data capture and improve patient workflow. To further enhance usability, it features simple icons and animation in a color display more commonly found in mobile devices than medical instruments.

The Xprecia Stride analyzer uses fresh capillary (fingerstick) whole blood and results are expressed as INR. It utilizes the same Dade Innovin reagent used by Siemens Healthineers central lab analyzers to minimize any potential for variability. Studies have shown the performance to be equivalent to a reference laboratory hemostasis system,1 with results available within minutes.

Safety features include a first-of-its kind test strip eject button that allows the user to eject a used test strip and easily dispose of it without touching it, minimizing potential biohazard exposure.

When taken together, all of these innovations ultimately enable better patient care as point-of-care PT/INR testing becomes critical to healthcare providers managing the growing number of patients that require anticoagulation therapy.

For more information: www.siemens.com

¹ White Paper, Fernando R, Jacobson AK, Kennedy S, Lessard C, Olson K, Scribner A, “PT/INR Test Performance of the Xprecia Stride Coagulation Analyzer Demonstrates Equivalency with Established Laboratory Hemostasis and Point-of-care Methods”

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
Shockwave Medical Announces CE Mark for Coronary Lithoplasty System and Activities at EuroPCR 2017
News | Cath Lab| May 23, 2017
Shockwave Medical announced last week CE Mark for the company’s Coronary Lithoplasty System for the treatment of...
Sponsored Content | Videos | Atrial Fibrillation| May 17, 2017
Hugh Calkins, M.D., FACC, FAHA, FHRS, director of cardiac arrhythmia services and professor of medicine at Johns Hopk
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Medtronic Reveal Linq implantable cardiac monitor

The Medtronic Reveal Linq implantable cardiac monitor is the smallest implantable monitor on the market. It is used as a long-term Holter monitor for 24-hour a day, 365-day a year patient monitoring. The device uses wireless connectivity to download the patient data with a patient bedside base unit to send the information over the internet so it is accessible by physicians.

Feature | Atrial Fibrillation| May 16, 2017
May 16, 2017 - The study using small, subcutaneous implantable cardiac monitors for long-term, 24-hour a day monitori
An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| May 16, 2017
May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 a
Guidelines updated for atrial fibrillation ablation at HRS 2017. Boston Scientific's Rhythmia mapping system
Feature | Atrial Fibrillation| May 15, 2017
May 15, 2017 – The Heart Rhythm Society (HRS) in joint partnership with several other electrophysiology societies iss
anticoagulants increase dementia risks
Feature | Antiplatelet and Anticoagulation Therapies| May 12, 2017
May 12, 2017 – A new study found that dementia rates increase with delays in starting anticoagulation treatment for
Analysis Shows Increased Risk of Early Stroke with New-Onset Atrial Fibrillation Post-TAVR, SCAI 2017 late-breaking clinical trial
News | Stroke| May 12, 2017
More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial...
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Overlay Init